Tuberculosis in children BY MBBSPPT.COM

Slides:



Advertisements
Similar presentations
JOURNAL CLUB Moderator-Dr NATESH.
Advertisements

Dr. Essam El Moghazy NTP Egypt
ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
Your name Institution/organization Meeting Date. Introduction.
TREATMENT OF TUBERCULOSIS, 2003
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
World Health Organization TB Case Definitions
TB GUIDELINE AND MANAGEMENT DR.JUSLEE DOUSIN. TB STORY TB induced skeletal defects as early as 8000BC Hippocrates called it “phthisis” in 460BC (coughing.
Group II Treatment regimens, hospitalization. DOT provision, outcome definitions, management of adverse drug reactions.
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
PULMONARY TUBERCULOSIS
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
Introduction to Tuberculosis
TUBERCULOSIS basic facts about TB
Diagnosis of TB.
Plans for Diagnosis and Management of Acute Pyelonephritis.
TUBERCULOSIS Diagnosis & treatment
TB 101: TB Basics and Global Approaches. Objectives Review basic TB facts. Define common TB terms. Describe key global TB prevention and care strategies.
“Don’t tell me TB is under control!” Understanding TB
Unit 9 Diagnosis and Treatment of Paediatric TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Unit 7 Treatment of TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Tuberculosis Research of INA-RESPOND on Drug-resistant
Extrapulmonary Site 2 :_____________________ Name (surname, first name) Age (in years) Sex F Alternative address Physical Address (in full) M INTERIM TUBERCULOSIS.
WORK UPS AND MANAGEMENT. Traditional and New Diagnostic Approaches DIAGNOSTICSAPPLICATIONS Traditional approaches - Symptom-based -TST -TB Culture --
TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.
Progress of the Singapore TB Elimination Programme (STEP)
.. Tuberculosis is a chronic infectious and communicable granulomatous disease caused by the Mycobacterium tuberculosis. Tuberculosis most commonly affects.
Revising the WHO TB Treatment Guidelines Process and new recommendations Malgosia Grzemska Matteo Zignol Stop TB Department World Health Organization DEWG.
Extrapulmonary Site 2 :_____________________ TUBERCULOSIS TREATMENT CARD BOTSWANA NATIONAL TUBERCULOSIS PROGRAMME Date RegisteredIN ToOUT RegisteredIN.
Module 2 TB Disease Transmission & Prevention. Pulmonary Tuberculosis Extra -Pulmonary TB an infectious disease caused by a microorganism called Mycobacterium.
Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
Tuberculosis in Children and Young Adults
TB IN CHILDREN & PREGNANT WOMEN
Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.
Tuberculosis in Children: Treatment and Monitoring Module 10B - March 2010.
TREATMENT OF TUBERCULOSIS: Prevention: BCG vaccination: It does not prevent infection but limits multiplication and spread of following infection so prevents.
Case Holding (TB-DOTS Training). Case holding a set of procedures which ensures that patients complete their treatment involves assignment of the appropriate.
EPIDEMIOLOGY OF PULMONARY TUBERCULOSIS. LEARNIN G OBJECTIVES State the diagnostic criteria of pulmonary tuberculosis Describe trend & state reasons for.
TB: The Elispot In The Room Dr Jessica Potter TB Research Registrar Barts Health NHS Trust.
Antituberculous treatment.
US TB Treatment Guidelines and DOT
Chapter 4 Cough or difficult breathing Case III
CHILDREN and HIV.
Tuberculosis (TB) PHCL 442 Lab Discussion 4 Raniah Al-Jaizani M.Sc.
Management of the Newborn When Maternal TB Suspected
Tuberculosis Part 2.
The story of Munya* (and us)
14/02/1396.
Infant born with mother Tuberculosis
Treatment of TB Disease
This is an archived document.
Dr Dawood Quiz questions.
Nucleic Acid Amplification Test for Tuberculosis
Epidemiology of pulmonary tuberculosis
Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors 
Dr Paul T Francis, MD Community Medicine College of Medicine, Zawia
اهمیت سل در چیست؟ حدود یک سوم جمعیت جهان(2 میلیارد نفر)با میکروب سل آلوده شده اند سالانه 9 میلیون نفر به سل فعال مبتلا می شوند هر ساله 1/5 تا 2 میلیون.
Presentation 10 Analysing results and defining cases
بسم الله الرحمن الرحيم.
... و خدایی که در این نزدیکیست
Tb: Screening & Diagnosis (1)
WHO TB GUIDELINES 2009/ 2010 WHAT IS NEW ?
DR-TB Case-finding and Referral Procedures
Goal Objectives Expected Outcomes
Chapter 4 Cough or difficult breathing Case III
Tuberculosis Tuberculosis (TB) is a bacterial infection, treatable by anti-TB drugs. It is a global problem, with the incidence varying across the world.
Procedures (Decision on Diagnosis based on Laboratory Results)
Presentation transcript:

Tuberculosis in children BY MBBSPPT.COM

Learning objective At the end of the lecture you should be able to understand: Epidemiology of childhood tuberculosis Case definitions of pediatric TB Diagnostic algorithm including investigations of childhood TB Categorization & Treatment of childhood TB as per National guidelines Chemo prophylaxis

Case definitions (RNTCP) Failure to respond: If within 12 weeks of compliant intensive phase treatment fails to achieve Bacteriological conversion from +ve to -ve AFB Clinical response Clinical improvement ( deterioration of condition) Relapse: A case of pediatric TB declared cured /completed therapy & again shows bacteriological & clinical evidence of TB

Case definitions (RNTCP) Treatment after default: A case who took at least 4 wks of ATT & comes after interruption of treatment for>=2 mths & has active disease (clinical/bacteriological) Others: For program purpose all retreatment cases where bacteriological confirmation could not be made but ATT started on clinical ground

Diagnostic algorithm of pediatric TB Persistent fever/cough>2 wks & or Loss of wt/no wt gain & or History of contact of infectious TB Sputum exam Sputum +ve Sputum –ve/N.A Received full course of antibiotic or Sick look or respiratory distress or Any other indications for Xray chest Smear +ve PTB Treat according to guidelines

Yes NO X-ray chest & Mx Course of antibioticx7days X-ray suggestive & Mx +ve No response Either or both -ve Review for alt diagnosis GL/IS/BAL Smear +ve Smear -ve Snear –ve PTB Treat as per guidelines Treat as per guidelines

Diagnostic algorithm of pediatric TB If X-ray chest- non specific shadow & Mx +ve or –ve  Rpt X-ray chest after a course of antibiotics if not given earlier  still persistent non specific shadow with Mx +ve or –ve  do GL/IS/BAL  smear +ve smear +ve PTB & treat as per guidelines. If smear is negative  look for alt diagnosis (if no alt diagnosis then treat as smear –ve PTB & treat as per guidelines)

Diagnostic algorithm of pediatric TB If X ray normal & Mx +ve  review for alt diagnosis & treat accordingly If no alt diagnosis established  look for extra pulmonary sites If no extra pulmonary sites involved take expert opinion (CT chest may be rqd.)

Diagnosis contd… USG abdomen for lymph nodes FNAC & biopsy of involved lymph nodes/organs CT scan rarely rqd. Sero diagnosis- antibody or antigen tests not recommended (TB Elisa) Interferon gama release assay –Early secretion antigen target 6 (ESAT6) & Culture filtrate protein(CFP10)- Quantiferron gold test and T- spot test TB PCR-NAAT –Poor sensitivity but real time PCR-recommended by WHO

Treatment categories Two categories: Treatment of all new cases Treatment of all previously treated cases Two phases of treatment: Intensive phase (2-3 mths) Continuation phase ( 4 – 7 mths, extendable up-to a total period of treatment to 12 months on a case to case basis) During intensive phase of TB meningitis, streptomycin to be replaced by tab. Ethambutol

DOTS All critically sick patients should be given daily treatment in the hospital At discharge to be referred to nearest DOTS center & alternate day therapy recommended At DOTS center separate box for individual child maintained Drugs are given at DOTS center & if child vomits in half hour- dose is repeated

Anti tubercular drugs First line Second line INH Rifampicin Ethambutol Pyrazinamide Streptomycin Rifabutin* Rifapentene* Cycloserine Para aminosalisylic acid Ethionamide Amikacin/Kanamycin Capreomicin Levofloxacin Moxifloxacin Gatifloxacin

Treatment categories & regimen Category of treatment Type of patient TB treatment regimens (intensive phase) TB treatment regimens (continuation phase) New cases New smear positive cases New smear negative pulmonary TB New extra pulmonary TB 2H3R3Z3E3* 4H3R3 Previously treated case *Relapse, failure to respond or treatment after default * Retreatment 2S3H3R3Z3E3 + 1H3R3Z3E3 5H3R3E3

Drug dosage INH- 10 mg/kg/day (max- 300 mg/day) Rifampicin -10-12 mg/kg/day (max- 600 mg/day) Ethambutol- 20-25 mg/kg/day (max 1500 mg/day) Pyrazinamide- 30-35 mg/kg/day (max 2000mg/day) Streptomycin- 15 mg/kg/day (max 1gm/day)

Chemoprophylaxis Indications: All asymptomatic contacts of a smear positive case( < 6 yrs age)after ruling out active disease & irrespective of BCG and nutritional status. HIV infected children in contact with smear positive case or Mx positive (>+ 5mm) but not active disease

Chemoprophylaxis contd…. All Mx positive children receiving immunosuppressive therapy e.g nephrotic syndrome, acute leukemia etc. Infant of mothers with TB diagnosed in pregnancy ( BCG vaccine can be given along with chemoprohylaxis Chemoprophylaxis is given with INH- 10 mg/kg/day x 6 mths.

MDR & XDR TB MDR TB- resistant to INH & Rifampicin X-DR TB – MDR TB+ resistant to Quinolones + resistant to any one of the following kanamycin/capreomycin/amikacin

TB bacillus concn & microscopic yeild No. of bacilli Observed Estimated concentration of bacilli per ml of specimen Probability of a positive result 0 in 100 or more field <1000 <10% 1-2 in 300 fields 5000-10000 50% 1-9 in 100 fields about 30 000 80% 1-9 in 10 fields about 50 000 90% 1-9 per field about 100 000 96.2% 10 or more per field about 500 000 99.95%

Thank You